DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Acquires $1,221,802.36 in Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg acquired 187,393 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was bought at an average price of $6.52 per share, with a total value of $1,221,802.36. Following the completion of the acquisition, the insider directly owned 7,951,858 shares of the company’s stock, valued at $51,846,114.16. This trade represents a 2.41% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg purchased 73,099 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $8.57 per share, for a total transaction of $626,458.43.
• On Monday, November 24th, Jan Stahlberg purchased 40,253 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $7.89 per share, with a total value of $317,596.17.
• On Friday, November 21st, Jan Stahlberg acquired 208,872 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $7.41 per share, with a total value of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg bought 128,426 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $7.41 per share, for a total transaction of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg bought 240,352 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $7.21 per share, with a total value of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg purchased 182,882 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $6.75 per share, with a total value of $1,234,453.50.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC traded down $0.02 during trading on Monday, reaching $8.76. The stock had a trading volume of 374,509 shares, compared to its average volume of 251,874. The firm’s fifty day moving average is $7.11 and its 200 day moving average is $5.70. DiaMedica Therapeutics, Inc. has a 52 week low of $3.19 and a 52 week high of $9.23. The stock has a market cap of $456.22 million, a price-to-earnings ratio of -12.34 and a beta of 1.31.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, research analysts forecast that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cooperman Leon G raised its holdings in shares of DiaMedica Therapeutics by 98.2% in the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock worth $22,463,000 after acquiring an additional 1,619,761 shares during the last quarter. Millennium Management LLC bought a new stake in DiaMedica Therapeutics during the 3rd quarter worth approximately $8,157,000. Geode Capital Management LLC increased its holdings in DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture raised its stake in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock worth $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares in the last quarter. 10.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DMAC. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Cantor Fitzgerald began coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They issued an “overweight” rating for the company. Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. Finally, TD Cowen began coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.